Skip to content

Clinical trials

Observational Pancreatic Neoplasms trials in China

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pancreatic Neoplasms Phase: Observational Country / region: China Clear all

113 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20081
20102
20121
20131
20143
20161
20173
20186
201911
202010
20219
202213
202312
202418
202513
20268

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status48
Recruiting32
Completed25
Not yet recruiting5
Active, not recruiting2
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Peking Union Medical College Hospital14
Changhai Hospital9
Fudan University6
Ruijin Hospital6
Second Affiliated Hospital, Zhejiang University, School of Medicine6
Zhejiang University5
Peking University Third Hospital4
RenJi Hospital4
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology4
Shanghai Zhongshan Hospital3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pancreatic Neoplasms113
Lung Neoplasms10
Stomach Neoplasms9
Disease8
Colorectal Neoplasms7
Liver Neoplasms7
Esophageal Neoplasms6
Pancreatitis, Chronic6
Adenoma, Islet Cell5
Breast Neoplasms5

Trials

Showing 1 to 25 of 113. Each trial links to its page on Pharma Observatory.

13 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.